SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a recent analyst price target increase, fueling community discussions about its valuation and future potential in the quantum computing sector. Bullish investors are enthusiastic about the momentum, while bears express concerns about the company's fundamentals and potential for a pullback, creating a highly volatile trading environment.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the community discusses its recent upward momentum and potential for further gains, with some eyeing a squeeze. Bullish investors are eagerly anticipating news and regulatory milestones, while also debating potential government involvement in the sector. Talk centers around technical analysis, short positions, and the long-term prospects of deep-sea mining for critical minerals.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Galecto (GLTO) is trending amidst high volatility and a low float, drawing comparisons to similar recent runners. The community is actively debating potential price movements, with some anticipating further gains while others foresee a sharp decline, fueled by short squeezes and profit-taking. Speculation is rampant despite the lack of apparent news, contributing to the stock's pump-and-dump chatter.

Siyata Mobile, Inc. engages in the provision of cellular communications systems for enterprise customers. It specializes in connected vehicle products for professional fleets, marketed under the Uniden Cellular and Siyata brands. The firm operates through the following geographical segments: Europe, the Middle East and Africa; Unites States; Canada; and Australia and New Zealand. The company was founded by Marc Seelenfreund on October 15, 1986 and is headquartered in Montreal, Canada.

Core AI Holdings Inc.

Core AI Holdings, Inc.

Core AI Holdings ($CHAI) is trending as the merger with Core Gaming finalizes, with the new ticker set to debut soon, though some users report trading difficulties on certain platforms. The community is weighing the impact of the merger and reverse split, while also speculating on future performance and potential short squeezes. Some are optimistic about the AI gaming sector and the company's revenue, while others voice concerns over platform issues and potential dilution.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. ($QBTS) is trending amid discussions about a potential short squeeze and overall momentum in the quantum computing sector. Community members are debating the company's valuation and future prospects, with some highlighting its potential in AI and clean technology, while others express concerns about dilution and competition from larger tech companies. There's also speculation about potential partnerships or acquisitions, contributing to the stock's recent volatility.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as retail traders discuss its high valuation and potential for a pullback, while others point to partnerships and government interest as reasons for continued bullishness. Debate centers around whether the stock is experiencing a short squeeze, and if it can sustain its current market capitalization given its revenue. The community is closely watching key price levels and potential impacts from future earnings reports.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending as investors discuss the implications of a recent private placement and its impact on the company's cash position and future strategy. Community members are debating the stock's valuation, potential acquisitions, and its position relative to other quantum computing companies. Some are bullish, citing the strong institutional demand, while others express concerns about dilution and question the long-term commercial viability of the technology.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin ($APP) is trending due to reports of an SEC probe into its data collection practices, sparking debate among investors. While some view the dip as a buying opportunity, citing Citigroup's recommendation, others express concerns about the potential impact on the company's future. The community is closely watching for further developments and the company's response.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid speculation of a partnership with Tesla, sparked by a teaser video and social media buzz. The community is actively discussing potential price targets and the likelihood of a short squeeze, while also considering Archer's broader prospects in the eVTOL market and military applications. Some investors are cautioning about a potential "buy the rumor, sell the news" scenario if the Tesla speculation doesn't materialize.

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

NuCana plc - ADR

NuCana plc

NuCana ($NCNA) is trending as traders discuss its low float and potential for a squeeze, drawing comparisons to $SPRB's recent surge. Anticipation is building around upcoming cancer treatment data presentations in October, with some speculating on merger possibilities and significant price targets. The community notes the company's strong cash runway into 2029, which further fuels optimism.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Momentum Stocks to Buy for July 14th

ELDN, KDDIY and PENG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14, 2025.

New Strong Buy Stocks for July 14th

WIT, KNOP, PENG, ELDN and KDDIY have been added to the Zacks Rank #1 (Strong Buy) List on July 14, 2025.

Eledon Pharmaceuticals Enacts Key Proposals and Board Changes

Eledon Pharmaceuticals (ELDN) just unveiled an announcement. Eledon Pharmaceuticals, Inc. stockholders convened on July 10, 2024, approving key pro...

Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence

Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney transplant patients. Analysts anticipate significant...

Eledon Pharmaceuticals Risks Shareholder Equity Dilution Amidst Private Placement and Potential Stock Issuances

Eledon Pharmaceuticals, Inc. (ELDN) has disclosed a new risk, in the Share Price & Shareholder Rights category. Eledon Pharmaceuticals, Inc. faces...

Eledon Pharmaceuticals: A Strong Buy on the Back of Promising Clinical Trials and a Solid Financial Footing

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals (ELDN Research Report), with a p...

Eledon Pharmaceuticals reports Q4 EPS (32c), consensus (39c)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following...

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ( Eledon ) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company's...

Eledon Pharmaceuticals (NASDAQ:ELDN) Rating Reiterated by HC Wainwright

Eledon Pharmaceuticals (NASDAQ:ELDN  Get Free Report)s stock had its buy rating reissued by analysts at HC Wainwright in a note issued to investors on Friday, Benzinga...

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.24	--	--	N/A
Q2 '25	-$0.23	-$0.13	43.48%	BEAT
Q1 '25	-$0.26	-$0.08	69.62%	BEAT
Q4 '24	-$0.31	-$0.64	-105.35%	MISSED
Q3 '24	-$0.31	-$0.32	-1.59%	MISSED

ELDN
Eledon Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ELDN News

ELDN Eledon Pharmaceuticals Inc